Automated Dispensing Machines Market Set to Boom Rapidly, Witnessing Strong Growth Through 2033 | Omnicell, BD, Swisslog, ScriptPro, Capsa Healthcare
Coherent Market Insights has released a comprehensive report on the Automated Dispensing Machines Market, forecasting strong growth through 2033. The report analyzes industry trends, competitive dynamics, and regional performance, featuring key players like Omnicell, BD, and Swisslog. It offers crucial insights for business leaders, investors, and strategists, covering market segmentation, research methodology, and strategic recommendations.
Asia Pacific Pharmacy Automation Market Is Going to Boom |• Omnicell • McKesson Corporation
Worldwide Market Reports has released a new research study on the "Asia Pacific Pharmacy Automation Market," forecasting its growth from 2026 to 2033. The report offers an in-depth analysis of market drivers, challenges, competitive landscape, and segmentation, utilizing both primary and secondary research. Key players like Omnicell and McKesson Corporation are highlighted, and the study provides insights for stakeholders to make informed investment decisions.
Omnicell (NASDAQ: OMCL) CEO Randall Lipps receives 90,939-share RSU grant
Omnicell (NASDAQ: OMCL) CEO Randall A. Lipps was granted 90,939 restricted stock units (RSUs) on April 1, 2026, as part of the company's equity incentive plan. The RSUs, valued at $0.00 per share, will vest over three years, with one-third vesting on the first anniversary and the remainder in equal installments on the second and third anniversaries. Following this grant, Lipps directly holds 535,531.0741 shares of Common Stock, in addition to shares held indirectly in trusts for his wife and children.
Omnicell (OMCL) grants 25,132 RSUs to EVP Corey Manley
Omnicell (OMCL) EVP & Chief Legal/Admin Officer Corey J. Manley was granted 25,132 Restricted Stock Units (RSUs) as part of the company's equity incentive plan. These RSUs were valued at $0.00 per share and will vest over a three-year period, with one-third vesting on the first anniversary and the remaining two-thirds in equal installments on the second and third anniversaries. Following this grant, Manley directly holds a total of 121,849.3392 shares of Omnicell common stock.
Omnicell Inc stock: Steady performer in healthcare tech – buy now?
Omnicell Inc (OMCL) is presented as a stable investment in healthcare technology, specializing in automated medication management for hospitals and pharmacies. The article highlights Omnicell's secure market position due to its integrated systems, recurring revenue model, and strong presence in North America. It suggests that Omnicell is a compelling option for investors seeking long-term reliability in the healthcare sector, despite competitive and economic risks.
Omnicell (OMCL) grants 46,296 RSUs to EVP and COO Nnamdi Njoku
Omnicell (OMCL) has granted 46,296 Restricted Stock Units (RSUs) to its EVP and Chief Operating Officer, Nnamdi Njoku, as part of the company's equity incentive plan. These RSUs, which carry no cash cost to Njoku, will vest over a three-year period, with one-third vesting on April 1, 2027, and the remainder in equal installments on the second and third anniversaries of the April 1, 2026 grant date. Following this transaction, Njoku directly holds 161,535.4457 shares of Omnicell common stock.
Omnicell (OMCL) CFO receives 37,037 RSU award, holdings reach 69,969 shares
Omnicell (OMCL) CFO Harlan Baird Radford was granted 37,037 Restricted Stock Units (RSUs) as part of the company's equity incentive plan. This award increases his direct holdings to 69,969 shares of Common Stock. The RSUs will vest in a staggered schedule: one-third on the first anniversary of the grant date, and the remaining two-thirds in equal installments on the second and third anniversaries.
Omnicell (OMCL) CAO granted 5,556 RSUs in new equity award
Omnicell's VP and Chief Accounting Officer, Brian H. Nutt, was granted 5,556 Restricted Stock Units (RSUs) as part of the company's equity incentive plan, increasing his direct holdings to 23,085.6135 shares. The RSUs were awarded at no cash cost and will vest over three years, with one-third vesting on the first anniversary and the remainder in equal installments on the second and third anniversaries. This is described as a routine compensation event designed for long-term executive retention rather than a market signal.
Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell shares are falling, what you need to know
This article indicates that shares of Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell are currently experiencing a decline. The title suggests that the content would provide an explanation for these drops, but the article text itself is not provided.
Millennium Group (OMCL) discloses 2,288,570 shares, a 5.0% holding
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have disclosed a shared beneficial ownership of 2,288,570 shares of Omnicell (OMCL) common stock, representing a 5.0% stake. This filing, a Schedule 13G, indicates a passive investment rather than an intent to control the company. The shares are held by entities over which the reporting persons have voting and investment discretion, governed by a Joint Filing Agreement dated March 31, 2026.
Pharmacy Automation Systems Market is expected to hit US$ 12.05 billion by 2033 | Major Companies - Omnicell, B. Braun Medical Inc., Baxter., ICU Medical, Inc.
The global Pharmacy Automation Systems Market, valued at US$ 6.95 billion in 2024, is projected to reach US$ 12.05 billion by 2033, growing at a CAGR of 7.0% from 2025-2033. This growth is driven by technologies that streamline medication dispensing, packaging, storage, and inventory management, enhancing accuracy and patient safety. Key players include Omnicell, B. Braun Medical Inc., Baxter, and ICU Medical, Inc., with significant recent developments in the US and Japan focusing on robotic dispensing, cloud-connected platforms, and AI-driven solutions.
Omnicell, Inc. Experiences Revision in Its Stock Evaluation Amid Market Volatility
Omnicell, Inc., a small-cap company in the Computers - Software & Consulting sector, has seen its stock price decline and performance lag behind the S&P 500 over the past year. The stock has experienced significant volatility, with technical indicators showing a mixed picture of bearish and mildly bullish signals across different timeframes. While its stock price sits at $32.75, a drop from its previous close, it has a 52-week range of $22.66 to $55.00, indicating considerable price fluctuation.
Assenagon Asset Management S.A. Has $11.70 Million Stake in Omnicell, Inc. $OMCL
Assenagon Asset Management S.A. significantly increased its stake in Omnicell, Inc. by 83.6% in Q4 2025, bringing its total holding to 258,231 shares valued at approximately $11.7 million. Despite Omnicell missing Q4 EPS estimates and providing cautious Q1 and FY 2026 guidance, analysts largely maintain positive ratings with a consensus "Moderate Buy" and a target price of $58.50. The company's stock, which opened at $32.75 and was down about 7.0%, has a market capitalization of $1.49 billion and a high trailing P/E ratio, while institutional investors own 97.70% of the stock.
Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell Shares Are Falling, What You Need To Know
Shares of several companies including Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell experienced significant drops in the afternoon session. This decline is attributed to escalating uncertainty from the U.S.-Iran conflict and policy deadlines set by the Trump administration, leading to market fears of prolonged conflict and rising oil prices. Although the market may overreact to such news, these price drops could present buying opportunities for high-quality stocks.
JPMorgan Chase & Co. Has $15.69 Million Position in Omnicell, Inc. $OMCL
JPMorgan Chase & Co. significantly reduced its stake in Omnicell, Inc. (NASDAQ:OMCL) by 94.2% in the third quarter, now holding 515,352 shares valued at approximately $15.69 million. Despite this reduction, Omnicell maintains a "Moderate Buy" consensus rating from analysts with an average target price of $58.50, although recent earnings missed expectations. The article also notes recent insider selling and other institutional investment activities in OMCL stock.
Should You Continue to Hold OMCL Stock in Your Portfolio?
Omnicell (OMCL) is advancing the autonomous pharmacy model, expanding its SaaS and Expert Services portfolio through strategic acquisitions and new platform launches. While the company's solid financial health and robust product pipeline present tailwinds, challenges such as higher operating costs and difficult hospital spending trends raise concerns for its operational results. Despite a recent decline in stock performance, Omnicell has shown a strong average earnings surprise of 33.6% over the trailing four quarters.
Omnicell, Inc. (NASDAQ:OMCL) Given Consensus Rating of "Moderate Buy" by Analysts
Analysts have given Omnicell, Inc. (NASDAQ:OMCL) a consensus "Moderate Buy" rating, with an average 12-month price target of $58.50. This comes despite the company missing quarterly EPS expectations and having a high P/E ratio. Several institutional investors have adjusted their stakes, and an EVP recently sold a significant number of shares.
Pharmaceutical Unit Dose Packaging Market Is Going to Boom | AptarGroup Inc. • Omnicell Inc. • Becton
Coherent Market Insights has released a new report, "Pharmaceutical Unit dose Packaging Market," analyzing current trends, growth drivers, challenges, and opportunities from 2026-2033. The report offers insights into market dynamics, regional outlook, and competitor landscape, featuring major companies like AptarGroup Inc., Omnicell Inc., and Becton, Dickinson and Company. Employing both primary and secondary research, it aims to help businesses forecast profitability and make informed strategic decisions.
OMCL PE Ratio & Valuation, Is OMCL Overvalued
Omnicell Inc (OMCL) is considered to be in the "Fair zone" with a forward P/E ratio of 25.62, which is fairly valued compared to its five-year average. The fair price for OMCL is estimated to be between $25.05 and $49.59 using a relative valuation method. Despite robust revenue growth, its current P/S ratio of 1.66 is significantly lower than competitor averages, and its P/B ratio is higher than its 3-year average but lower than its 5-year average.
Pharmacy Inventory Management Software Solutions And Cabinets
Coherent Market Insights has released a report analyzing the "Pharmacy Inventory Management Software Solutions And Cabinets Market," covering industry trends, growth opportunities, and competitive dynamics from 2026-2033. The comprehensive study provides insights for business leaders, entrepreneurs, and investors, detailing market segmentation by type (centralized/decentralized dispensing systems, software solutions) and applications (hospital, independent, and long-term care pharmacies). Major market players like Omnicell, Inc. and Becton, Dickinson and Company are highlighted, alongside a regional analysis across North America, Europe, Asia-Pacific, South America, and MEA.
Medication Therapy Management Market Current Impact to Make Big Changes | CVS Health, Walgreens, Omnicell
The Medication Therapy Management (MTM) market, valued at USD 4.5 billion in 2025, is projected to reach USD 9.5 billion by 2033, growing at a CAGR of 10.4%. This growth is driven by increasing chronic diseases, rising healthcare costs, governmental support, and technological advancements like digital health platforms and AI. Key players include CVS Health and Walgreens, with North America dominating the market and Asia-Pacific showing the fastest growth.
Omnicell trying to close in on key technical measure
This article states that Omnicell is approaching a key technical measure. No further details are available in the provided content.
Omnicell (NASDAQ:OMCL) EVP Corey Manley Sells 7,405 Shares
Omnicell (NASDAQ:OMCL) EVP Corey Manley sold 7,405 shares of the company's stock on March 16th for over $256,000, reducing his stake by 7.11%. This insider sale comes as Omnicell reported mixed Q4 earnings, missing EPS consensus but slightly exceeding revenue expectations, and provided Q1 and full-year 2026 guidance. The stock experienced a 2.3% uptick following the news, with analysts holding a "Moderate Buy" consensus and a target price of $55.29 despite recent varied ratings.
Omnicell (OMCL) EVP Manley reports PSU vesting, tax withholding and share sale
Omnicell's EVP Corey J. Manley reported the vesting of performance-based restricted stock units (PSUs) on March 15, 2026, where he acquired 22,445 shares. Simultaneously, 3,819 shares were withheld for tax purposes, and he subsequently sold 7,405 shares on March 16, 2026, under a pre-arranged trading plan. Following these transactions, Manley directly holds 96,717.3392 shares of Omnicell common stock.
Omnicell (OMCL) COO gains 37,409 shares; 8,456 withheld for taxes
Omnicell's EVP and COO, Nnamdi Njoku, acquired 37,409 common shares from the vesting of performance-based restricted stock units (RSUs) after the company met specific stock performance objectives. Of these, 8,456 shares were withheld for tax purposes at a price of $34.40 per share. Following these transactions, Njoku directly holds 115,239.4457 Omnicell common shares, with remaining RSUs scheduled to vest in quarterly installments over three years.
Omnicell (NASDAQ: OMCL) CEO RSUs vest; shares withheld for taxes
Omnicell, Inc. CEO Randall A. Lipps reported the vesting of 79,494 performance-based restricted stock units (RSUs) after the company met specific stock performance objectives. In connection with this vesting, 15,642 shares were withheld for tax liabilities at $34.40 per share. Following these transactions, Lipps directly holds 444,592 Common Stock shares, with additional shares held indirectly in trusts.
Q4 2025 Omnicell Inc Earnings Call Transcript
Omnicell Inc. (OMCL) reported its Q4 2025 earnings, with revenues, bookings, and annual recurring revenue (ARR) exceeding guidance midpoint, driven by strong demand for point-of-care connected devices and the introduction of TitanXT. Despite these positive indicators, the company reported a GAAP EPS loss and a decrease in non-GAAP gross margin due to tariff costs and product mix shifts. Omnicell anticipates facing approximately $15 million in tariff costs impacting its 2026 financials.
OMCL (NASDAQ: OMCL) affiliate sales; 7,405 restricted shares vest on 03/15/2026
OMNICELL, INC. (OMCL) filed a Form 144 disclosing proposed sales of common stock and recent affiliate dispositions. The filing indicates a restricted stock vesting of 7,405 shares on March 15, 2026, tied to compensation, and details prior sales by Corey Manley. The sales by Manley included 278 shares on December 16, 2025, for $12,037.40; 6,106 shares on January 8, 2026, for $304,689.40; and 4,243 shares on February 17, 2026, for $155,251.37.
Pier Capital LLC Reduces Stock Position in Omnicell, Inc. $OMCL
Pier Capital LLC significantly reduced its stake in Omnicell, Inc. ($OMCL) by 34.6% in the third quarter, now holding 115,714 shares valued at $3.52 million. This move comes as Omnicell missed its quarterly EPS consensus, though revenue largely met forecasts, and the company provided Q1 and FY2026 EPS guidance. Analysts generally rate Omnicell as a "Moderate Buy" with an average target price of $54.50, despite an insider sale by EVP Corey J. Manley.
Benchmark reiterates Omnicell stock rating on product cycle outlook
Benchmark reiterated a Buy rating and $60.00 price target on Omnicell (NASDAQ:OMCL) shares, following an investor meeting with the company's CFO, despite a recent 15% stock decline. Analyst Bill Sutherland highlighted the multi-year opportunity for accelerating revenue growth and margin expansion driven by new products Titan XT and Omnisphere. The company's CFO, Baird Radford, anticipates non-GAAP EBITDA margin returning to pre-pandemic levels and growing at twice the pace of mid-single-digit revenue guidance for the year, with plans to offer financing for customers to level the playing field with competitors.
Omnicell (NASDAQ:OMCL) Rating Increased to Hold at Zacks Research
Zacks Research has upgraded Omnicell (NASDAQ:OMCL) from a "strong sell" to a "hold" rating, with other firms like Bank of America and Benchmark also raising their ratings or price targets. The company recently reported an EPS miss of $0.40 against an expected $0.47, though revenue was largely in line, and provided Q1 and FY 2026 guidance. Omnicell, a healthcare technology company specializing in medication management solutions, has a market capitalization of $1.70 billion and a trailing P/E of 937.23.
Telepharmacy Market Set to Witness Rapid Growth Through 2033
Coherent Market Insights has published a report titled "Telepharmacy Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast, 2026-2033," outlining the market's rapid growth potential. The report provides a thorough analysis of market dynamics, competitive positioning, and future opportunities, making it a reliable resource for business leaders and investors. Key highlights include business descriptions, SWOT analysis of leading companies like Omnicell Inc. and Cerner Corporation, market segmentation by type and application, and regional analysis.
How Omnicell Inc. (OMCL) Affects Rotational Strategy Timing
This article analyzes Omnicell Inc. (OMCL) using AI models to determine its effect on rotational strategy timing. It highlights strong sentiment supporting an overweight bias, identifies a risk-reward short setup, and details three tailored trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis.
Quantbot Technologies LP Purchases Shares of 25,813 Omnicell, Inc. $OMCL
Quantbot Technologies LP recently acquired 25,813 shares of Omnicell, Inc. (NASDAQ:OMCL) in Q3, valued at approximately $786,000, initiating a new position in the company. Institutional ownership of Omnicell is high at 97.7%, with several major funds increasing their stakes, although an executive recently sold a portion of their shares. Analysts have mixed views on the stock, with some raising price targets while others lowered ratings, resulting in an average "Hold" rating, and the company missed its recent quarterly EPS estimate.
What is Zacks Research's Estimate for Omnicell Q2 Earnings?
Zacks Research has lowered its Q2 2026 EPS estimate for Omnicell to $0.19 and maintains a "Strong Sell" rating on the stock, with a full-year EPS consensus of $1.09. Other analysts present a more varied view, with an average "Hold" rating and a consensus price target of $54.50. Omnicell recently missed Q4 earnings estimates but its revenue was in line, and the company provided Q1 and FY 2026 guidance.
Omnicell Leans Into Healthcare IT As ANiGENT Deal Reshapes Growth Story
Omnicell (NasdaqGS:OMCL) is transitioning from a hardware vendor to a Healthcare IT company, driven by its acquisition of ANiGENT to enhance drug diversion detection capabilities. This strategic shift aims to move towards recurring software and services revenue, away from hardware sales, despite past share price challenges and margin pressures. The success of this pivot will depend on the integration of ANiGENT's technology, customer adoption of software, and effective competition against other healthcare IT providers.
Pharmacy Repackaging Systems Market Is Going to Boom Rapidly |
Coherent Market Insights has released a new research study on the Global "Pharmacy Repackaging Systems Market" for 2026, forecasting its growth until 2033. The report segments the market by type (Unit Dose, Blister, Automated), application (Hospital, Retail, Long-Term Care Pharmacies), and region, providing an in-depth analysis of market trends, drivers, restraints, and competitive landscape. Key players profiled include Omnicell Inc., Swisslog Healthcare, and Parata Systems LLC.
Intech Investment Management LLC Sells 135,679 Shares of Omnicell, Inc. $OMCL
Intech Investment Management LLC significantly reduced its stake in Omnicell (NASDAQ:OMCL) by selling 135,679 shares, now holding 52,568 shares valued at approximately $1.60 million. This comes as Omnicell missed its Q4 earnings expectations with EPS of $0.40 against an anticipated $0.47, though revenue was in line at $314 million. Analyst sentiment is mixed, leading to a consensus "Hold" rating with an average revised price target of $54.50.
Omnicell Shows Rising Price Performance With Jump To 81 RS Rating
Omnicell (OMCL) recently had its Relative Strength (RS) Rating upgraded from 76 to 81, indicating improved price performance compared to other stocks. This proprietary rating measures market leadership over the past 52 weeks. The article highlights Omnicell's consistent upgrades and strong technical strength, suggesting its stock is showing market leadership.
Omnicell Leans Into Healthcare IT As ANiGENT Deal Reshapes Growth Story
Omnicell (NasdaqGS:OMCL) is transitioning from a hardware vendor to a Healthcare IT company, focusing on a software and services-led model, particularly after acquiring ANiGENT for drug diversion detection. This strategic shift aims to move away from cyclical hardware sales towards recurring revenue, despite a mixed share price history and current pressure on profit margins. The success of this pivot will depend on integrating new technologies, driving customer adoption, and competing effectively in the healthcare IT market.
Omnicell Leans Into Healthcare IT As ANiGENT Deal Reshapes Growth Story
Omnicell (NasdaqGS:OMCL) is transitioning from a hardware vendor to a healthcare IT company, focusing on software and services after acquiring ANiGENT for drug diversion detection. This strategic pivot aims to establish recurring revenue streams and improve long-term financial stability, despite past share price challenges and current operational risks related to integration and competition. The success of this move will depend on how quickly Omnicell can convert its customer base to software and services and manage potential risks.
JPMorgan Chase & Co. Sells Omnicell, Inc. $OMCL Shares
JPMorgan Chase & Co. significantly decreased its stake in Omnicell, Inc. by 94.2% during the third quarter, selling 8,362,010 shares. This move leaves JPMorgan Chase & Co. with only 1.12% of Omnicell and could indicate a shift in investor sentiment or portfolio strategy regarding the healthcare technology company. Investors are expected to monitor whether other institutional investors will follow suit or if Omnicell can attract new shareholders to compensate for this large reduction.
Omnicell, Inc. $OMCL Shares Sold by JPMorgan Chase & Co.
JPMorgan Chase & Co. significantly reduced its stake in Omnicell, Inc. by 94.2% in the third quarter, selling over 8 million shares. This comes as Omnicell missed EPS expectations for the quarter, though revenue was in line, and the company provided Q1 and FY2026 EPS guidance. Institutional ownership remains high at 97.7%, but insider selling has also been noted, and analysts hold a mixed "Hold" consensus rating for the stock.
Omnicell Stock Analysis: Strong Performance vs. Long-Term Concerns - News and Statistics
Omnicell's stock has significantly outperformed the S&P 500 recently, but analysts highlight long-term concerns regarding its financial performance. Despite strong stock performance, the company has experienced mediocre sales growth, a decrease in adjusted operating margin, and declining earnings per share over the past five years. This suggests that the current market optimism reflected in its valuation may not be justified by the underlying business trends.
3 Reasons to Steer Clear of OMCL and One Alternative Stock Worth Buying
Despite Omnicell's recent stock surge, the article advises investors to be cautious due to weak long-term revenue expansion (5.8% annualized), declining adjusted operating margins (-9.2 percentage points over five years), and decreasing earnings per share (-8.6% annually). The article suggests that the current forward P/E of 23.6 for OMCL indicates high expectations that may not be met, recommending investors consider alternative high-performing stocks in software or other sectors identified by AI analysis.
Roubaix Capital LLC Purchases Shares of 76,383 Omnicell, Inc. $OMCL
Roubaix Capital LLC recently acquired 76,383 shares of Omnicell, Inc. (NASDAQ:OMCL) worth approximately $2,326,000, representing a 0.17% stake in the company. Omnicell reported Q4 earnings that missed analyst estimates but saw a 2.3% year-over-year revenue increase, with institutional investors owning 97.70% of its stock. Analyst sentiment is mixed, with a "Moderate Buy" consensus and a target price of $54.50, despite recent insider stock sales.
Vanguard Group Inc. Has $170.89 Million Holdings in Omnicell, Inc. $OMCL
Vanguard Group Inc. recently reduced its stake in Omnicell, Inc. by 0.4%, now holding 5,612,001 shares valued at approximately $170.89 million, representing 12.22% of the company. Omnicell missed its quarterly EPS estimate and provided Q1 and FY 2026 guidance. Analysts have a "Moderate Buy" consensus rating with a target price of $54.50, despite mixed recent rating and price target changes.
Assessing Omnicell (OMCL) Valuation As ANiGENT Deal Accelerates Shift To Software And Services
Omnicell (OMCL) is gaining investor attention due to its strategic shift towards software and services, particularly with the ANiGENT acquisition, focusing on drug diversion detection and recurring revenue. While the company shows recent momentum with a 13.79% share price return over 90 days, its 5-year total shareholder return is down 66.95%, indicating long-term weaknesses. Despite trading at a reported 12% intrinsic discount and having a fair value narrative of $57.43, its P/S ratio signals potential valuation risks.
3 Reasons to Avoid OMCL and 1 Stock to Buy Instead
This article explains why investors should avoid Omnicell (OMCL) despite its recent stock performance. The authors present three main reasons: disappointing long-term revenue growth, a shrinking adjusted operating margin, and a downward trend in earnings per share. They suggest that the current valuation of OMCL is too optimistic given these factors and recommend looking for other investment opportunities.
Assessing Omnicell (OMCL) Valuation As ANiGENT Deal Accelerates Shift To Software And Services
Omnicell (OMCL) is gaining investor attention following its ANiGENT acquisition, which emphasizes a shift towards software and services, particularly in drug diversion detection and recurring revenue. Despite a recent 13.79% share price return over 90 days, the company has seen a long-term decline of 66.95% over five years. Currently trading at US$41.10, Omnicell is assessed as 28.4% undervalued, with a fair value pegged at $57.43 per share, largely driven by its software and cabinet refresh strategy, though its P/S ratio signals potential risks.
